Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafolecimab + sintilimab + SOX
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Tafolecimab + sintilimab + SOX is an investigational combination regimen being evaluated for the treatment of proficient mismatch repair (pMMR) or microsatellite stable (MSS) advanced gastric and gastroesophageal junction adenocarcinoma. The regimen consists of **tafolecimab**, a fully humanized monoclonal antibody targeting PCSK9; **sintilimab**, a monoclonal antibody targeting the PD-1 receptor; and **SOX chemotherapy**, which is a combination of S-1 (a fluoropyrimidine prodrug) and oxaliplatin. The rationale for this combination is based on preclinical evidence suggesting that PCSK9 inhibition can enhance anti-tumor immunity by increasing the cell surface expression of MHC class I molecules, thereby improving antigen presentation and sensitizing immunologically "cold" tumors to PD-1 blockade and chemotherapy.
- Brand names
- Sinuofei
- Other names
- tafolecimab + sintilimab + S-1 + oxaliplatinIBI306 + IBI308 + SOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on tafolecimab + sintilimab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafolecimab + sintilimab + SOX.